The Split
Healthcare isn't one sector. It's two completely different businesses operating under the same label. On one side: pharmaceutical companies, biotech, medical devices. On the other: health insurance. The cash flow numbers make this abundantly clear.
Twenty companies in this sector earned A-grades. Six got F's. The median FCF margin sits at 16.1%, respectable by any standard. But that median hides a chasm. The top performers are running margins above 20%. The bottom five are barely generating positive cash, and one is burning through it at a catastrophic rate.
This isn't about temporary weakness or cyclical pressure. This is structural. The A-grade companies make products. The F-grade companies process claims.
The Cash Machines
Gilead leads the sector at 29.1% FCF margin with an improving trend. AbbVie sits right behind at 27.6%, also improving. Bristol-Myers posts 25.5%, though the trend turned negative. Zoetis, the animal health spinoff from Pfizer, holds 23.2%. IDEXX, another animal health play, sits at 22.9%.
These aren't outliers. Vertex cleared 20%. Amgen hit 20.7%. Danaher came in at 20.2%. Regeneron reached 19.3%. Johnson & Johnson still manages 19.1% despite a declining trend. This is the core of the sector: established pharmaceutical and medical device companies converting revenue to cash at rates most industries can't touch.
The consistency matters as much as the margins. Twenty of 29 companies show improving trends. Three are stable. Only six are declining. When 69% of a sector is moving in the right direction, that's not luck.
What separates the top tier from the rest isn't just margin percentage. It's balance sheet discipline. Gilead and AbbVie both maintain strong positions without excessive leverage. The sector average debt-to-FCF ratio of 7.7x sounds high, but that's pulled up by a few outliers. The A-grade companies mostly keep debt manageable relative to their cash generation.
The Insurance Problem
Then there's the other healthcare sector.
UnitedHealth Group, the largest health insurer in the country by revenue, generates a 3.4% FCF margin. F-grade. Cigna sits at 3.1%, also an F. CVS Health, which owns Aetna, manages 1.8% with a declining trend. Elevance (formerly Anthem) scrapes out 1.5%. Humana barely registers at 0.1%.
These aren't small regional players. These are Fortune 50 companies with massive revenue bases. UnitedHealth did $371 billion in revenue last year. But revenue scale doesn't translate to cash generation when your business model involves negotiating rates, processing claims, and managing medical costs you don't fully control.
The improving trends at UnitedHealth, Humana, and Elevance suggest management knows they have a problem and they're working on it. CVS and Cigna going the other direction is more concerning. When you're already at 1.8% and trending down, there's not much margin for error.
The insurance players also carry debt. UnitedHealth's balance sheet isn't terrible relative to its size, but when you're generating cash at 3.4% margins, debt becomes a bigger constraint than it would be for Gilead at 29.1%.
The Moderna Situation
Moderna sits at the bottom with a -133.1% FCF margin. That's not a typo. The company is burning cash faster than it generates revenue. The improving trend notation is technically accurate but misleading. When you're at -133%, any movement looks like improvement.
Moderna rode the COVID vaccine wave to temporary profitability. That wave ended. Now they're back to being a clinical-stage biotech with one commercial product facing declining demand. The cash burn reflects heavy R&D spending on a pipeline that hasn't produced a second act yet.
This is the risk profile of biotech. High margins when you have a blockbuster. Brutal cash consumption when you don't. Moderna got sorted into healthcare because that's where biotechs go, but the business model has more in common with venture-backed tech than with Gilead's established drug portfolio.
What This Means
When we last looked at healthcare in late May, the story was similar: strong pharma and device companies, struggling insurers. The gap has widened slightly. More companies moved to improving trends. The insurance players still can't figure out how to generate meaningful cash.
If you're evaluating healthcare exposure, ask which healthcare you're actually getting. A portfolio of Gilead, AbbVie, and Danaher looks nothing like a position in UnitedHealth or CVS. Same sector label. Completely different cash profiles.
The sector's strength comes from the product side. Twenty A-grades out of 29 companies is exceptional. But six F-grades concentrated in one business model is a red flag for that specific corner of healthcare.
Pharma and devices work. They generate cash, maintain reasonable balance sheets, and show improving trends. The insurance model struggles. Until that changes, the sector split will persist.
Get our best analysis
Free cash flow insights and stock grades, delivered to your inbox.
Aureus Research
Data-driven analysis grounded in free cash flow fundamentals. Every grade, every insight, backed by real numbers from public financial statements.
More Research
Healthcare: 17 A-Grades, Seven Insurance Disasters
Pharma and devices print 20%+ margins. Health insurers struggle to break 3%.
Healthcare: 16 A-Grades, Seven Insurance Failures
Healthcare has the highest A-grade count of any sector, but health insurance is broken at the free cash flow level.
Healthcare: 16 A-Grades and a Broken Insurance Model
Pharma prints cash at 25%+ margins. Health insurers are burning through it at 2%. Same sector, different planets.